Killing Cancer Loudly: Onchilles Pharma's Neutrophil-Derived Path to Pan-Cancer Therapy

What It Covers

Onchilles Pharma cofounders Court Turner and Lev Becker explain how their lead compound N17350 exploits neutrophil elastase and elevated histone H1 to selectively kill cancer cells while activating immunity, with $41M raised, GMP manufacturing complete, and first-in-human trials launching across solid tumors in Australia and the US.

Key Questions Answered

• •Selective cytotoxicity via histone H1: N17350 targets a universal cancer vulnerability — elevated histone H1 — present across more than 50 tested cancer cell lines and 45 patient ovarian samples. Because non-cancer cells lack this vulnerability, the drug kills tumor cells while sparing immune cells, enabling simultaneous direct tumor killing and immune system activation in a single mechanism.
• •Immunogenic cell death as differentiator: N17350 induces "loud" immunogenic cell death rather than the immunologically silent killing typical of standard chemotherapy. This distinction matters clinically: traditional chemo suppresses immunity while killing tumors, whereas N17350's mechanism trains the immune system during the killing process, potentially overcoming resistance in both chemo-refractory and immunologically cold tumor settings.
• •Resistance avoidance enables repeat dosing: Unlike targeted therapies such as KRAS inhibitors that lose efficacy against heterogeneous tumor populations, N17350 shows no resistance development following repeated administration in preclinical models. Clinicians can re-administer the drug if tumors regrow, a property one head-and-neck oncologist flagged as enabling tongue-tumor reduction without surgery or systemic chemotherapy.
• •Capital-efficient clinical model with 8 FTEs: Onchilles reached IND approval and GMP manufacturing of thousands of clinical doses on $41M with only eight full-time employees by outsourcing to CROs and consultants. Biotech founders building first-in-class biologics should prioritize manufacturing stability and scale-up investment early — Onchilles spent five years on CMC before entering the clinic, which resolved key investor risk concerns.
• •Pan-cancer partnering strategy over independent expansion: Rather than building a large internal organization, Onchilles is pursuing multiple indication-specific or geographic partnerships with pharma companies. The intratumorally delivered N17350 targets accessible solid tumors first — head and neck, skin, breast — while the systemically delivered NU002 follows 12–14 months behind, creating two distinct partnering assets across different delivery contexts.